Clinical Trials Logo

Anemia, Hemolytic, Autoimmune clinical trials

View clinical trials related to Anemia, Hemolytic, Autoimmune.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06067048 Not yet recruiting - Lymphoma Clinical Trials

Zanubrutinib in Primary Cold Agglutinin Disease

HOVON169CAD
Start date: February 1, 2024
Phase: Phase 2
Study type: Interventional

Cold agglutinin disease (CAD) is defined as a chronic autoimmune hemolytic anemia (AIHA) with a monospecific direct antiglobulin test (DAT) strongly positive for C3d and the presence of cold agglutinins (CA; titer ≥ 64 at 4°C). Patients may have a B-cell clonal lymphoproliferative disorder (LPD) detectable in blood or marrow but no clinical or radiological evidence of malignancy. CAD can lead to AIHA, peripheral ischemic symptoms (cold-induced peripheral symptoms such as acrocyanosis etc.), or both. The CAs are typically monoclonal IgM antibodies produced by the clonal B-cells, usually IgM kappa with specificity for the I antigen on erythrocytes. There is no curative treatment. Current treatment options include rituximab monotherapy, however this has only a limited and short-lasting effect. Rituximab in combination with chemotherapy induces deeper and more durable responses, however since CAD patients typically do not have an overt malignancy this comes with concerns about short- and long-term toxicity. Novel complement inhibitors may be effective for the hemolysis but are not expected to be effective against cold induced peripheral symptoms while this is directly IgM mediated. Bruton Tyrosine Kinase inhibitors (BTKis) are effective in many B-cell lymphoproliferative disorders including the IgM producing clone of Waldenström macroglobulinemia (WM) and were very effective on both AIHA and peripheral ischemic symptoms in patients with CAD based on retrospective data.

NCT ID: NCT05711264 Not yet recruiting - Clinical trials for Autoimmune Hemolytic Anemia

Presence of Circulating Cluster of Differentiation 4 Positive 28 Null T Helper Lymphocytes(CD4+CD28-) in Patients With Autoimmune Hemolytic Anemia.

Start date: January 30, 2023
Phase:
Study type: Observational

1. Study the presence of circulating CD4+/CD28 null T lymphocytes in AIHA either Idiopathic or Secondary. 2. Role of CD4+/CD28 null T lymphocytes in monitoring response to therapy in AIHA.

NCT ID: NCT04814394 Not yet recruiting - Clinical trials for Autoimmune Hemolytic Anemia

The Significance of Release of T-follicular Helper and T-follicular Regulatory Cells in Autoimmune Haemolytic Anemia Before and After Tratment

fhfr
Start date: April 1, 2022
Phase:
Study type: Observational

we study the circulating T-follicular regulatory and T-follicular regulatory cells in autoimmune hemolytic anemia.

NCT ID: NCT03912129 Not yet recruiting - Evans Syndrome Clinical Trials

Autoimmune Cytopenia: Genetics and Pathophysiological Mechanism in Pediatric Evans Syndrome

ACTION
Start date: May 6, 2019
Phase: N/A
Study type: Interventional

Characterization of the genetic causes, and of the immunopathological clinical and biological manifestations in children with pediatric Evans syndrome included in a prospective national observational cohort of rare diseases.